MOUNTAIN VIEW, Calif. — July 11, 2025 — Heartflow, Inc., the leader in AI technology for coronary artery disease (CAD), today announced Heartflow Plaque Analysis will be included in updated cardiac imaging guidelines by radiology benefit manager EviCore, which provides coverage... Continue Reading
This August, Boston will host one of the most influential gatherings in cardiovascular medicine as the American Society for Preventive Cardiology (ASPC) convenes its 2025 Congress on Cardiovascular Disease Prevention. Continue Reading
PASADENA, Calif.--(BUSINESS WIRE)--Jun. 23, 2025-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has completed enrollment in SHASTA-3, SHASTA-4, and MUIR-3, the company’s global Phase 3 clinical studies designed to support regulatory submissions for marketing... Continue Reading
INDIANAPOLIS, June 17, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Verve Therapeutics, Inc. (Nasdaq: VERV), a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease, today announced a definitive agreement for Lilly to acquire Verve. Read more... Continue Reading
INDIANAPOLIS, June 16, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the highest approved doses of Zepbound (tirzepatide)—12.5 mg and 15 mg—will soon be available in single-dose vials for $499 per month through LillyDirect's Self Pay Pharmacy Solutions and... Continue Reading
ATLANTA, GA, UNITED STATES, June 16, 2025 /EINPresswire.com/ -- ALYKA Health, a digital health company that partners with providers to empower patients to improve their cardiovascular health and outcomes, announced that it is now a supporting partner of the American Society for Preventive... Continue Reading
Despite advances in our knowledge and understanding of cardiovascular health, cardiovascular disease (CVD) remains the No. 1 killer of men and women in the United States. Continue Reading
Cardiovascular disease remains the leading cause of morbidity and mortality worldwide, driven in large part by two modifiable risk factors: high blood pressure (hypertension) and high cholesterol (hypercholesterolemia). Continue Reading
TARRYTOWN, N.Y., June 02, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced a strategic in-licensing agreement with Hansoh Pharmaceuticals Group Company Limited (“Hansoh”) to acquire exclusive clinical development and commercial rights outside of... Continue Reading
TARRYTOWN, N.Y., June 02, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced interim results from the ongoing Phase 2 COURAGE trial investigating novel combinations of semaglutide (GLP-1 receptor agonist) and trevogrumab (anti-GDF8/anti-myostatin) with or... Continue Reading
Even if you are well aware that heart disease is the leading killer of women, the fact that it’s responsible for one in three deaths is still a striking stat. But there’s hope: most cardiovascular disease is preventable, say top cardiologists. Continue Reading
INDIANAPOLIS, April 17, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive topline Phase 3 results from ACHIEVE-1, evaluating the safety and efficacy of orforglipron compared to placebo in adults with type 2 diabetes and inadequate glycemic control with diet and... Continue Reading
